Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar;18(3):269-286.
doi: 10.1080/17460441.2023.2174097. Epub 2023 Feb 16.

Glioblastoma treatment slowly moves toward change: novel druggable targets and translational horizons in 2022

Lidia Gatto  1 , Enrico Franceschi  2 , Alicia Tosoni  2 , Vincenzo Di Nunno  1 , Stefania Bartolini  2 , Alba Ariela Brandes  2
Affiliations

Glioblastoma treatment slowly moves toward change: novel druggable targets and translational horizons in 2022

Lidia Gatto et al. Expert Opin Drug Discov. 2023 Mar.

Abstract

Introduction: Glioblastoma (GBM) is the most common primary brain tumor in adults. GBM treatment options have been the same for the past 30 years and have only modestly extended survival, despite aggressive multimodal treatments. The progressively better knowledge of GBM biology and a comprehensive analysis of its genomic profile have elucidated GBM heterogeneity, contributing to a more effective molecular classification and to the development of innovative targeted therapeutic approaches.

Areas covered: This article reports all the noteworthy innovations for immunotherapy and targeted therapy, providing insights into the current advances in trial designs, including combination therapies with immuno-oncology agents and target combinations.

Expert opinion: GBM molecular heterogeneity and brain anatomical characteristics critically restrain drug effectiveness. Nevertheless, stimulating insights for future research and drug development come from innovative treatment strategies for GBM, such as multi-specific 'off-the-shelf' CAR-T therapy, oncolytic viral therapy and autologous dendritic cell vaccination. Disappointing results from targeted therapies-clinical trials are mainly due to complex interferences between signaling pathways and biological processes leading to drug resistance: hence, it is imperative in the future to develop combinatorial approaches and multimodal therapies.

Keywords: CAR T cells; Glioblastoma; NTRK; bevacizumab; buparlisib; dendritic cell vaccine; immunotherapy; larotrectinib; oncolytic virotherapy; regorafenib; toca 511.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

LinkOut - more resources